El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134(6):1752-63. [DOI:10.1053/j.gastro.2008.02.090] [PMID]

Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology. 2006; 60(2):89-98. [DOI:10.1016/j.critrevonc.2006.06.001] [PMID]

Zhang J, Lou W. A key mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network linked to diagnosis and prognosis of hepatocellular carcinoma. Frontiers in Oncology. 2020; 10:340. [DOI:10.3389/fonc.2020.00340] [PMID] [PMCID]

Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, et al. Mechanisms of hepatocellular carcinoma progression. World Journal of Gastroenterology. 2019; 25(19):2279-93. [DOI:10.3748/wjg.v25.i19.2279] [PMID] [PMCID]

Hudlebusch HR, Skotte J, Santoni-Rugiu E, Zimling ZG, Lees MJ, Simon R, et al. MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Research. 2011; 71(12):4226-35. [DOI:10.1158/0008-5472.CAN-10-3810] [PMID]

Yang S, Zhang Y, Meng F, Liu Y, Xia B, Xiao M, et al. Overexpression of multiple myeloma SET domain (MMSET) is associated with advanced tumor aggressiveness and poor prognosis in serous ovarian carcinoma. Biomarkers. 2013; 18(3):257-63. [DOI:10.3109/1354750X.2013.773082] [PMID]

Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t (4; 14) multiple myeloma cells. Blood. 2011; 117(1):211-20. [DOI:10.1182/blood-2010-07-298349] [PMID] [PMCID]

Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Molecular Cell. 2011; 44(4):609-20. [DOI:10.1016/j.molcel.2011.08.042] [PMID] [PMCID]

Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, et al. MMSET deregulation affects cell cycle progression and adhesion regulons in t (4; 14) myeloma plasma cells. Haematologica. 2009; 94(1):78-86. [DOI:10.3324/haematol.13426] [PMID] [PMCID]

Ezponda T, Popovic R, Shah MY, Martinez-Garcia E, Zheng Y, Min DJ, et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene. 2013; 32(23):2882-90. [DOI:10.1038/onc.2012.297] [PMID] [PMCID]

Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Molecular Cell. 2013; 49(1):80-93. [DOI:10.1016/j.molcel.2012.10.008] [PMID] [PMCID]

Zhao LH, Li Q, Huang ZJ, Sun MX, Lu JJ, Zhang XH, et al. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer. Cell Death Disease. 2021; 12(11):974. [DOI:10.1038/s41419-021-04267-6] [PMID] [PMCID]

Topchu I, Pangeni RP, Bychkov I, Miller SA, Izumchenko E, Yu J, et al. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cellular and Molecular Life Sciences. 2022; 79(6):285. [DOI:10.1007/s00018-022-04321-2] [PMID] [PMCID]

Chen R, Chen Y, Zhao W, Fang C, Zhou W, Yang X, et al. The role of methyltransferase NSD2 as a potential oncogene in human solid tumors. OncoTargets and Therapy. 2020; 13:6837-46. [DOI:10.2147/OTT.S259873] [PMID] [PMCID]

Zhou P, Wu LL, Wu KM, Jiang W, Li Jd, Zhou Ld, et al. Overexpression of MMSET is correlation with poor prognosis in hepatocellular carcinoma. Pathology Oncology Research. 2013; 19(2):303-9. [DOI:10.1007/s12253-012-9583-z] [PMID]

Teoh PL. Basic animal cell culture technique. Methods in biotechnology. Manassas: ATCC: The Global Bioresource Center.; 2018. [Link]

Fazeli M, Soleimanjahi H, Ghaemi A, Farzanepour M, Amanzadeh A, Hashemi SR. Efficacy of HPV-16 E7 based vaccine in a TC-1 tumoric animal model of cervical cancer. Cell Journal (Yakhteh). 2011; 12(4):483-8. [Link]

Hayon T, Dvilansky A, Shpilberg O, Nathan I. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia. Leukemia & Lymphoma. 2003; 44(11):1957-62. [DOI:10.1080/1042819031000116607] [PMID]

Tallarida RJ, Murray RB. PHARM/PCS Version 4.2. Wynnewood: PharmSofT; 2005. [Link]

Wang J, Wang C, Bu G. Curcumin inhibits the growth of liver cancer stem cells through the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway. Experimental and Therapeutic Medicine. 2018; 15(4):3650-8. [DOI:10.3892/etm.2018.5805] [PMID] [PMCID]

Du Y, Shi X, Ma W, Wen P, Yu P, Wang X, et al. Phthalates promote the invasion of hepatocellular carcinoma cells by enhancing the interaction between Pregnane X receptor and E26 transformation specific sequence 1. Pharmacological Research. 2021; 169:105648. [DOI:10.1016/j.phrs.2021.105648] [PMID]

Tsai CF, Hsieh TH, Lee JN, Hsu CY, Wang YC, Kuo KK, et al. Curcumin suppresses phthalate-induced metastasis and the proportion of cancer stem cell (CSC)-like cells via the inhibition of AhR/ERK/SK1 signaling in hepatocellular carcinoma. Journal of Agricultural and Food Chemistry. 2015; 63(48):10388-98. [DOI:10.1021/acs.jafc.5b04415] [PMID]

Song D, Lan J, Chen Y, Liu A, Wu Q, Zhao C, et al. NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein. Oncogene. 2021; 40(16):2952-67. [DOI:10.1038/s41388-021-01747-z] [PMID]

Chen R, Chen Y, Zhao W, Fang C, Zhou W, Yang X, et al. The role of methyltransferase NSD2 as a potential oncogene in human solid tumors. OncoTargets and Therapy. 2020; 13:6837-46. [DOI:10.2147/OTT.S259873] [PMID] [PMCID]

García-Carpizo V, Sarmentero J, Han B, Graña O, Ruiz-Llorente S, Pisano DG, et al. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation. Scientific Reports. 2016; 6:32952.[DOI:10.1038/srep32952] [PMID] [PMCID]

Han X, Piao L, Xu X, Luo F, Liu Z, He X. NSD2 promotes renal cancer progression through stimulating Akt/Erk signaling. Cancer Management and Research. 2020; 12:375-83. [DOI:10.2147/CMAR.S222673] [PMID] [PMCID]

Stangl-Kremser J, Lemberger U, Hassler MR, Garstka N, Grubmüller B, Haitel A, et al. The prognostic impact of tumour NSD2 expression in advanced prostate cancer. Biomarkers. 2020; 25(3):268-73. [DOI:10.1080/1354750X.2020.1734861] [PMID]